Systemetic Investigation of Repeated Administration of Temsirolimus on the Antihyperglycemic Activity of Mifepristone and Risk of Cancer

Authors:

DOI: DOI: 10.23880/apct-16000143

Volume 3, Issue 4

Abstract

To determine the association between temsirolimus (anticancer) and those of antihyperglycimic agent mifepristone in DXM induced rabbits. Blood glucose levels are estimated up to 24 hrs. Our findings have shown a significant relationship between, dexamethasone treated rabbits pretreatment with temsirolimus(3.5 mg/kg) for 7 days, which decreased the onset of hypoglycemia i.e. from 2 hour to 1 hour, i.e. (18.12+.9886 to 16.15+.7592) , has significantly enhanced the peak hypoglycemia (24.91+1.173%) before treatment (44.14+.3518 % ) after treatment ( p<.001), at 8th hour and duration of hypoglycemia was also significantly enhanced from 18 hrs to more than 24 hrs induced by mifepristone (9.33mg/kg)(17.87+1.202 to 24.28+1.730),(p<.001). This study indicates that therapeutic drug

Keywords: Temsirolimus; Mifepristone; DMX

View PDF